Liraglutide in Children and Adolescents with Type 2 Diabetes

Tamborlane, William V.; Barrientos-Pérez, Margarita; Fainberg, Udi; Frimer-Larsen, Helle; Hafez, Mona; Hale, Paula M; Jalaludin, Muhammad Yazid; Коваренко, Маргарита; Libman, Ingrid; Lynch, Jane; Rao, Paturi; Shehadeh, Naim; Turan, Serap; Weghuber, Daniel; Barrett, Timothy

doi:10.1056/nejmoa1903822

Cited by 252 publications

(267 citation statements)

References 15 publications

Supporting

Mentioning

217

Contrasting

Unclassified

Order By: Relevance

“…In this context, it is noteworthy that reduction in BMI‐SDS and BMI was increasing throughout the study period and may be even more pronounced if the treatment duration was extended beyond the 6‐month period in the current study. Of note, this is in line with a recent study, in which adolescents with obesity and T2DM were randomly assigned to receive the GLP‐1 RA liraglutide or placebo for a 26‐week double‐blind period, followed by a 26‐week open‐label extension period, and showed that a reduction in BMI was not significant after 6, but 12 months …”

Section: Discussionsupporting

confidence: 86%

A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 86%

A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Liraglutide is currently the only GLP‐1 RA approved in paediatric patients following results from the ellipse trial, but use is QD 14,72 . Incidence of GI AEs in the ellipse trial was as expected for this drug class, and a higher proportion of patients experienced serious AEs and hypoglycaemic episodes vs placebo 72 . There is a trial underway with QW exenatide ER in paediatric patients with T2D 73…”

Section: Resultsmentioning

confidence: 88%

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes

Trujillo

2020

J Clin Pharm Ther

View full text Add to dashboard Cite

show abstract

“…A recent randomized clinical trial in children aged 10-17 years with type 2 diabetes demonstrated the addition of subcutaneous liraglutide (up to 1.8 mg daily) to metformin (with or without basal insulin) as safe and effective to decrease A1C (estimated decrease of 1.06 percentage points at 26 weeks and 1.30 at 52 weeks), although it did increase the frequency of gastrointestinal side effects (191). In June 2019, the U.S. Food and Drug Administration approved liraglutide injection for treatment of pediatric patients aged 10 years or older with type 2 diabetes (192).…”

Section: Management Of Cardiovascular Risk Factorsmentioning

confidence: 99%

13. Children and Adolescents: Standards of Medical Care in Diabetes−2020

2019

Diabetes Care

225

106

View full text Add to dashboard Cite

The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidencegrading system for ADA's clinical practice recommendations, please refer to the Standards ofCare Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. The management of diabetes in children and adolescents cannot simply be derived from care routinely provided to adults with diabetes. The epidemiology, pathophysiology, developmental considerations, and response to therapy in pediatric-onset diabetes are different from adult diabetes. There are also differences in recommended care for children and adolescents with type 1 as opposed to type 2 diabetes. This section first addresses care for children and adolescents with type 1 diabetes and next addresses care for children and adolescents with type 2 diabetes. Figure 13.1 provides guidance on managing new-onset diabetes in youth with overweight or obesity before type 1 or type 2 diabetes is diagnosed and so applies to all youth with overweight or obesity. Lastly, guidance is provided in this section on transition of care from pediatric to adult providers to ensure that the continuum of care is appropriate as the child with diabetes develops into adulthood. Due to the nature of clinical research in children, the recommendations for children and adolescents with diabetes are less likely to be based on clinical trial evidence. However, expert opinion and a review of available and relevant experimental data are summarized in the American Diabetes Association (ADA) position statements "Type 1 Diabetes in Children and Adolescents" (1) and "Evaluation and Management of Youth-Onset Type 2 Diabetes" (2). The ADA consensus report "Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities" (3) characterizes type 2 diabetes in children and evaluates treatment options but also discusses knowledge gaps and recruitment challenges in clinical and translational research in youth-onset type 2 diabetes. Monogenic diabetes (neonatal diabetes and maturity-onset diabetes in the young [MODY]), which often present in youth, are discussed in section 2 "Classification and Diagnosis of Diabetes" (

show abstract

Liraglutide in Children and Adolescents with Type 2 Diabetes

Cited by 252 publications

References 15 publications

A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity

A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes

13. Children and Adolescents: Standards of Medical Care in Diabetes−2020

Contact Info

Product

Resources

About